Bionano Genomics Inc
For the period ended Dec 31, 2023. Filed Mar 5, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 5, 2024
BNGO$1.23+6.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
BIONANO GENOMICS, INC
Consolidated Statements of Cash Flows
| Years Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Operating activities: | ||
| Net loss | $(232,493,000) | $(132,596,000) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization expense | 13,708,000 | 9,621,000 |
| Goodwill impairment | 77,280,000 | — |
| Amortization of financing lease right-of-use asset | 204,000 | 219,000 |
| Amortization (accretion) of interest on securities | (539,000) | 638,000 |
| Net realized loss (gain) on investments | 23,000 | 66,000 |
| Non-cash lease expense | 56,000 | 478,000 |
| (Benefit) expense from deferred income taxes | — | 1,760,000 |
| Stock-based compensation | 15,178,000 | 22,417,000 |
| Cost of leased equipment sold to customer | 382,000 | 204,000 |
| Change in fair value of contingent consideration | (1,462,000) | 316,000 |
| Change in fair value of convertible notes payable and option liability | (575,000) | — |
| Loss on High Trail Agreement | 18,826,000 | — |
| Contingent consideration cash payment in excess of acquisition-date fair value | (1,000,000) | — |
| Changes in operating assets and liabilities (net of assets acquired and liabilities assumed in acquisition) | ||
| Accounts receivable | (2,296,000) | (2,251,000) |
| Inventory | (4,150,000) | (23,676,000) |
| Prepaid expenses and other current assets | 1,213,000 | (3,197,000) |
| Other assets | (5,020,000) | (1,130,000) |
| Accounts payable | (1,995,000) | 1,949,000 |
| Accrued expenses and contract liabilities | (2,521,000) | 366,000 |
| Net cash used in operating activities | (125,181,000) | (124,816,000) |
| Investing activities: | ||
| BioDiscovery acquisition, return of purchase consideration from escrow | — | 694,000 |
| Purigen acquisition, return of purchase consideration from escrow | 96,000 | — |
| Purigen acquisition, net of cash acquired | — | (31,344,000) |
| Purchases of property and equipment | (1,691,000) | (2,408,000) |
| Sale of property and equipment | — | 26,000 |
| Construction in process | — | (792,000) |
| Purchases of intangible assets | — | (102,000) |
| Purchase of available for sale securities | (111,264,000) | (84,195,000) |
| Sale and maturities of available for sale securities | 137,017,000 | 200,888,000 |
| Net cash provided by investing activities | 24,158,000 | 82,767,000 |
| Financing activities: | ||
| Principal payments of financing lease liability | (47,000) | (36,000) |
| Proceeds from sale of common stock | 57,697,000 | 23,128,000 |
| Offering expenses on sale of common stock | (1,444,000) | (578,000) |
| Proceeds from sale of common stock under employee stock purchase plan | 107,000 | 150,000 |
| Proceeds from warrant and option exercises | 23,000 | 343,000 |
| Proceeds from High Trail Agreement | 80,000,000 | — |
| Payments on convertible notes payable | (9,000,000) | — |
| Debt issuance costs related to High Trail Agreement | (4,521,000) | — |
| Contingent consideration milestone payment | (9,000,000) | — |
| Net cash provided by financing activities | 113,815,000 | 23,007,000 |
| Effect of exchange rates on cash and cash equivalents and restricted cash | 65,000 | (38,000) |
| Net increase (decrease) in cash and cash equivalents and restricted cash | 12,857,000 | (19,080,000) |
| Years Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash and cash equivalents and restricted cash at beginning of period | 5,491,000 | 24,571,000 |
| Cash and cash equivalents and restricted cash at end of period | $18,348,000 | $5,491,000 |
| Reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets to the total amounts reported on the consolidated statements of cash flows | ||
| Cash and cash equivalents | 17,948,000 | 5,091,000 |
| Restricted cash | 400,000 | 400,000 |
| Total cash and cash equivalents and restricted cash at end of period | $18,348,000 | $5,491,000 |
| Supplemental disclosure of cash flow information | ||
| Cash paid for interest | $1,648,000 | $298,000 |
| Cash paid for operating lease liabilities | $2,586,000 | $1,622,000 |
| Supplemental disclosure of non-cash financing and investing activity | ||
| Contingent consideration related to Purigen acquisition | $— | $12,970,000 |
| Operating lease liabilities resulting from obtaining and modifying right-of-use assets | $— | $517,000 |
| Transfer of instruments and servers from inventory into property and equipment, net | $10,979,000 | $7,244,000 |
| Property and equipment included in accounts payable | $6,000 | $90,000 |
| Debt issuance costs included in accounts payable | $150,000 | $— |
| Conversion of convertible notes payable into common stock at fair value | $6,542,000 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.